Quantcast
Last updated on April 17, 2014 at 15:50 EDT

Health News Archive - June 03, 2010

EAST HANOVER, N.J., June 3 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that a Phase III study of Afinitor® (everolimus) tablets plus best supportive care met its primary endpoint, showing the drug significantly extended progression-free survival, or time without tumor growth, in patients with advanced pancreatic neuroendocrine tumors (NET).

PARIS, June 3, 2010 /PRNewswire/ -- The personalised medicine association EPEMED, a European not-for-profit organisation bringing together global forces in personalised medicine, has today announced the appointment of Dr. Anne Bruinvels, an entrepreneur in personalised healthcare, as Executive Director and board member.

GENEVA, Switzerland, June 3, 2010 /PRNewswire/ -- - PEARL I Trial Meets Primary Efficacy and Safety Endpoints - PregLem Preparing for Submission to the European Medicines Agency in 2010 PregLem, the European specialty biopharmaceutical company focused on women's reproductive medicine, announces positive Phase III data from its second pivotal study (PEARL I) for its lead product Esmya (ulipristal acetate), as an effective treatment for uterine fibroids (myoma) - a condition that affects millions of women worldwide. The final set of positive Phase III results, combined with the positive PEARL II results announced in May 2010, will enable PregLem to submit a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) by the end of 2010.

SEATTLE, June 3 /PRNewswire/ -- In a landmark decision, Oregon regulators have given first-ever official US approval to a brand of medical marijuana hydroponics nutrients. Oregon and most other states have regulatory agencies that examine fertilizers and hydroponics plant supplements to determine the legitimacy, ingredients and effectiveness of plant growth products. Advanced Nutrients co-founder Michael Straumietis welcomes the news that Oregon's government proffered formal approval for an Advanced Nutrients formula designed for a specific strain of medical marijuana. "Regulatory approval is a breakthrough for the medical marijuana community," Straumietis explains.

TOKYO, June 3 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) announced today the completion of the initial tender offer for all outstanding shares of common stock in OSI Pharmaceuticals, Inc. (Nasdaq: OSIP). The initial offer period expired at 12:00 midnight, New York City time, on June 2, 2010.

LAS VEGAS, June 3 /PRNewswire-FirstCall/ -- Cord Blood America, Inc.

TOKYO, June 3 /PRNewswire/ -- We are pleased to announce that the Phase II clinical study of UF-021, product name Ocuseva (TM), which we are developing as a therapeutic drug for retinitis pigmentosa (note 1), has been completed. Retinitis pigmentosa is an intractable disease where therapeutic drugs or therapeutic methods have not been established yet.

NEW YORK, June 3 /PRNewswire-USNewswire/ -- United Spinal Association has partnered with BOTOX(®) maker Allergan, Inc., actor Henry Winkler, and four national patient advocacy organizations to educate the public on the low awareness and under-diagnosis of upper limb spasticity.

BOTHELL, WA and VANCOUVER, June 3 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, OncoGenex's President and Chief Executive Officer, will present at the 9th Annual Needham Healthcare Conference on June 10 at 10:40 a.m.

LAKELAND, Fla. June 3 /PRNewswire/ -- Intelimedix, a business intelligence company focused on multi-relational data mining and advanced analytics for faster, more accurate decision-making, announced a strategic partnership with integrated loss control service provider TC3 Health, Inc.